Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy

The sustained benefit of immunotherapy-based regimens in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) failure is debatable. Neither Checkmate-722 nor Keynote-789 reached the prespecified statistical level of clinical be...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Wu, Yan Ling, Bao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, Yuan-Sheng Zang
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/4/e008818.full
Tags: Add Tag
No Tags, Be the first to tag this record!